What is B. Riley’s Forecast for CAPR Q2 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at B. Riley issued their Q2 2026 earnings per share estimates for Capricor Therapeutics in a research note issued to investors on Sunday, September 14th. B. Riley analyst M. El-Saadi anticipates that the biotechnology company will post earnings of ($0.42) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics’ Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at $2.34 EPS.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%.

Several other analysts have also recently issued reports on CAPR. HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Capricor Therapeutics in a research note on Thursday, September 11th. Jones Trading reduced their target price on Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, June 25th. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. Finally, Roth Capital reduced their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $22.56.

Capricor Therapeutics Trading Up 3.0%

CAPR stock opened at $6.22 on Tuesday. The stock has a market capitalization of $284.38 million, a price-to-earnings ratio of -3.79 and a beta of 0.73. The firm’s 50-day moving average price is $7.23 and its two-hundred day moving average price is $9.69. Capricor Therapeutics has a 12-month low of $4.59 and a 12-month high of $23.40.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Krilogy Financial LLC increased its stake in shares of Capricor Therapeutics by 9.6% in the 1st quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 2,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock valued at $1,079,000 after purchasing an additional 2,314 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 2,361 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Capricor Therapeutics by 10.9% during the first quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 2,822 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Capricor Therapeutics by 31.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 3,162 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.